16 results on '"MiKaela Olsen"'
Search Results
2. Comparing Modes of Cancer Drug Safety Training for Multi-Professional Learners: A Roadmap for Adapting from In-Person to Distance Simulation
- Author
-
Michelle Aebersold, Anna Tankerslety, Ann Marie Lee Walton, Shawna Kraft, Karen B. Farris, Mikaela Olsen, Martha Polovich, Brenda K. Shelton, Guy H. Montgomery, Marylee Scherdt, and Christopher R. Friese
- Abstract
Background: Cancer drug therapy is a high-volume, high-risk clinical encounter that requires close coordination across interprofessional clinical teams. Purpose: The Multi-Professional Oncology Safety and Simulation Training (MOSST) program, supported by the National Cancer Institute was launched in Fall 2018. The original workshop was conducted in person. As the COVID pandemic hit the program was transitioned to an on-line/distance simulation program. Method: The full day workshop was moved to an on-line platform using Zoom and the in-person simulations were re-developed as video simulations. We then evaluated learner outcomes identically in each modality using the evaluation metrics from our original workshop. Discussion: We found that the use an of online modality to deliver the MOSST workshop resulted in a high-quality educational experience for the learners and the educational outcomes were comparable.
- Published
- 2023
3. Supply chain disruptions due to the SARS‐CoV‐2 pandemic lead to an unusual preanalytical error in measuring hemoglobin concentration in a large medical center
- Author
-
Samuel M. Law, Rochelle Hardy, Danna Anderson, Lona Small, Jennifer Hurley, Leon Beggs, Yanka Campbell, MiKaela Olsen, Tina Mancini‐Flegel, Al Valentine, Michael J. Borowitz, and Ivo M. B. Francischetti
- Subjects
General Medicine - Published
- 2022
4. Evaluation of an Interprofessional Training Program to Improve Cancer Drug Therapy Safety
- Author
-
Shawna Kraft, Christopher R. Friese, MiKaela Olsen, Brenda K. Shelton, Marylee Scherdt, Guy H. Montgomery, Michelle Aebersold, Karen B. Farris, and Martha Polovich
- Subjects
medicine.medical_specialty ,Cancer drugs ,MEDLINE ,Interdisciplinary Studies ,ORIGINAL CONTRIBUTIONS ,03 medical and health sciences ,0302 clinical medicine ,Pharmacotherapy ,Neoplasms ,Intervention (counseling) ,Humans ,Medicine ,Computer Simulation ,Intensive care medicine ,030504 nursing ,Oncology (nursing) ,business.industry ,Health Policy ,Cancer ,medicine.disease ,Anticancer drug ,Oncology ,030220 oncology & carcinogenesis ,0305 other medical science ,business ,Training program - Abstract
PURPOSE: Drug therapy for cancer is a high-risk, high-volume clinical intervention that requires interprofessional teams. Given the complexity of anticancer drug therapy and safety concerns, an interdisciplinary team developed a novel training program for oncology registered nurses and pharmacists to improve cancer drug safety. METHODS: Participants completed preworkshop learning assessments and received access to web-based modules on six topics: hazardous drug handling, drug extravasation, hypersensitivity reaction management, sepsis recognition, immune checkpoint inhibitor toxicities, and oral oncolytic adherence. In a 7-hour workshop, participants applied module content in interactive exercises and high-fidelity simulations. Preworkshop and postworkshop questionnaires assessed changes in knowledge and confidence in each topic. Program satisfaction and changes to clinical practice or policies were assessed 3 months after the workshop. RESULTS: Two hundred ninety-two nurses and 82 pharmacists applied to participate, and 103 (35%) and 44 (54%) have participated, respectively. Long-term follow-up data were available on 133 (90%) participants. Change scores in confidence to meet program objectives increased between pre- and postworkshop (range of increase 0.6-0.8, P < .01). Knowledge scores increased significantly between pre- and postworkshop (average improvement of 3.2 points, P < .01). Overall program satisfaction was high (mean 5.0, standard deviation [0.2] on a five-point scale). Seventy-seven (60%) reported that they had made at least one clinical practice or institutional policy change at 3 months. CONCLUSION: An interprofessional education program with online modules, in-person interactive sessions, and simulation activities is a promising strategy to deliver cancer drug safety content to practicing oncology clinicians.
- Published
- 2021
5. Report on 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination
- Author
-
Mary Lynn Moody, Patricia C. Kienle, Philip N. Johnson, MiKaela Olsen, John Fanikos, Christine Roussel, Lindsey B. Amerine, and Michael Gabay
- Subjects
Pharmacies ,Pharmacology ,Scope (project management) ,business.industry ,Health Policy ,Consensus conference ,Pharmacy ,Hazardous drugs ,Contamination ,medicine.disease ,Subject-matter expert ,Pharmaceutical Preparations ,Touch ,Hazardous waste ,Pharmaceutical Services ,Health care ,medicine ,Humans ,Medical emergency ,business ,medicine.drug - Abstract
Purpose The 2020 Safe to Touch Consensus Conference on Hazardous Drug Surface Contamination was convened in order to gather subject matter experts in the field of hazardous drug (HD) handling to develop consensus statements regarding surface contamination monitoring for adoption by stakeholders in the drug supply chain, policy, and healthcare arenas. Summary The Safe to Touch conference convened virtually on September 22, 24, and 26, 2020. An expert panel of healthcare providers with experience in HD handling, monitoring, and research; pharmacy and nursing operations; and medication safety led the conference. An experienced audience of approximately 25 reaction panel members provided feedback to the panel via a preconference survey, during the conference, and at a postconference virtual town hall. Additionally, expert speakers presented on a range of issues, including the impact of HD surface contamination on health, current regulations and standards, surface contamination monitoring technologies, and variables impacting surface contamination testing. Conclusion At the end of the conference, the expert panel developed 11 consensus statements and corresponding recommendations that should be widely disseminated in order to educate individuals regarding the impact of HD surface contamination and increase the scope of HD surface contamination monitoring. Institutions involved in the handling of HDs should set short- and long-term goals for implementation of applicable consensus statements.
- Published
- 2021
6. National Comprehensive Cancer Network Infusion Efficiency Workgroup Study: Optimizing Patient Flow in Infusion Centers
- Author
-
Diedra K. Frantz, Jessica Sugalski, Gina M. Szymanski, Connie Augustyniak, Jeanine Gordon, Sharol K. Kidd, Timothy Kubal, Robert W. Carlson, F. Marc Stewart, Diana Krause, Rosanna Fiorarancio Fahy, Penny J. Moore, Marisa A. Quinn, MiKaela Olsen, Daniel Mulkerin, and Rebecca L. Caires
- Subjects
medicine.medical_specialty ,MEDLINE ,Cancer Care Facilities ,Efficiency, Organizational ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,030212 general & internal medicine ,Workgroup ,Intensive care medicine ,Oncology (nursing) ,business.industry ,Health Policy ,Cancer ,Neoplasms therapy ,medicine.disease ,Patient flow ,Oncology ,Multicenter study ,Health Care Surveys ,030220 oncology & carcinogenesis ,business ,Delivery of Health Care - Abstract
PURPOSE: The National Comprehensive Cancer Network (NCCN) formed an Infusion Efficiency Workgroup to determine best practices for operating efficient and effective infusion centers. METHODS: The Workgroup conducted three surveys that were distributed to NCCN member institutions regarding average patient wait time, chemotherapy premixing practices, infusion chair use, and premedication protocols. To assess chair use, the Workgroup identified and defined five components of chair time. RESULTS: The average patient wait time in infusion centers ranged from 25 to 102 minutes (n = 23; mean, 58 minutes). Five of 26 cancer centers (19%) routinely mix chemotherapy drugs before patient arrival for patients meeting specified criteria. Total planned chair time for subsequent doses of the same drug regimens for the same diseases varied greatly among centers, as follows: Administration of doxorubicin and cyclophosphamide ranged from 85 to 240 minutes (n = 22); of FOLFIRINOX (folinic acid, fluorouracil, irinotecan hydrochloride, and oxaliplation) ranged from 270 to 420 minutes (n = 22); of rituximab ranged from 120 to 350 minutes (n = 21); of paclitaxel plus carboplatin ranged from 255 to 380 minutes (n = 21); and of zoledronic acid ranged from 30 to 150 minutes (n = 22) for planned total chair time. Cancer centers were found to use different premedication regimens with varying administration routes that ranged in administration times from zero to 60 minutes. CONCLUSION: There is a high degree of variation among cancer centers in regard to planned chair time for the same chemotherapy regimens, providing opportunities for improved efficiency, increased revenue, and more standardization across centers. The NCCN Workgroup demonstrates potential revenue impact and provides recommendations for cancer centers to move toward more efficient and more standard practices.
- Published
- 2019
7. Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition)
- Author
-
MiKaela Olsen, Kristine LeFebvre, Suzanne L. Walker, Elizabeth Prechtel Dunphy, MiKaela Olsen, Kristine LeFebvre, Suzanne L. Walker, and Elizabeth Prechtel Dunphy
- Subjects
- Immunotherapy, Chemotherapy
- Abstract
'Oncology nursing is a unique specialty that requires continuous learning to stay up to date on cancer pathophysiology, cutting-edge drugs, and the evidence-based management of cancer and cancer treatment-related toxicities. The Oncology Nursing Society's (ONS's) second edition of Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice provides nurses with the tools to understand how medications are used in cancer treatment, the effect of medication-related toxicities, and evidence-based recommendations to manage and treat these toxicities. This edition features many new cancer therapies approved since the 2019 publication. Each drug is categorized as chemotherapy, hormone, targeted, or immunotherapy agents. Extensive drug tables in the book provide nurses with tips for managing patients receiving these drugs. The expansion of oral antineoplastic therapies, alone or in combination with infusion therapy, requires that nurses review a patient's complete cancer treatment plan and consider the side effects, toxicities, and adherence to oral drugs to ensure patient tolerance and efficacy. This second edition has seen content expanded on the topic of genomics as we move forward in the world of personalized oncology. Health equity is approached with information discussing financial distress, cultural disparities, and health literacy. The latest guidelines and recommendations for treatment, symptom management, and survivorship have been integrated into this new text. This edition features a QR code, provided with the purchase of this book, to download quarterly drug updates. You will see new evidence related to many aspects of cancer nursing care incorporated into this edition, such as hypersensitivity response, safe handling of hazardous drugs, and more. The editors want to thank all of the contributors to this edition who worked tirelessly, despite a pandemic, to make this new edition a reality. This work builds on the knowledge of many generations of oncology nurses and has been used nationally and internationally to guide oncology nursing practice. We are proud to continue to serve oncology nurses worldwide with an essential resource to guide their practice'--
- Published
- 2023
8. Creative Strategies Implemented During the Coronavirus Pandemic That Will Impact the Future of Cancer Care
- Author
-
Alyssa A. Schatz, Jennie R. Crews, Lawrence N. Shulman, Pelin Cinar, James E. Bachman, MiKaela Olsen, Theresa Franco, Jessica Sugalski, and Timothy Kubal
- Subjects
2019-20 coronavirus outbreak ,Medical education ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Best practice ,Cancer ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Oncology ,Pandemic ,Medicine ,030212 general & internal medicine ,business - Abstract
The coronavirus pandemic has significantly impacted operations at leading cancer centers across the United States. In the midst of the chaos, at least one silver lining has emerged: the development of new, creative strategies for delivering cancer care that are likely to continue post pandemic. The NCCN Best Practices Committee, which is composed of senior physician, nursing, and administrative leaders at NCCN Member Institutions, conducted a webinar series in June 2020 highlighting the most promising and effective strategies to date. Experts from NCCN Member Institutions participated in the series to share their experiences, knowledge, and thoughts about the future of cancer care.
- Published
- 2020
9. Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice
- Author
-
MiKaela Olsen, Kristine LeFebvre, Kelly Brassil, MiKaela Olsen, Kristine LeFebvre, and Kelly Brassil
- Subjects
- Immunotherapy, Antineoplastic agents, Cancer--Treatment
- Abstract
Features 26 chapters examining multiple categories of cancer-care agents, including chemo, immunotherapy, molecularly targeted agents, and hormone therapy.
- Published
- 2019
10. Implementation of an Early Warning Scoring System to Identify Patients With Cancer at Risk for Deterioration
- Author
-
Ellen Evans, MiKaela Olsen, and Kathy Mooney
- Subjects
Adult ,Male ,Scoring system ,Risk Assessment ,InformationSystems_GENERAL ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Humans ,Medicine ,Cognitive Dysfunction ,030212 general & internal medicine ,Clinical care ,Aged ,Monitoring, Physiologic ,General Environmental Science ,Aged, 80 and over ,030504 nursing ,Warning system ,business.industry ,Nurse leaders ,Oncology Nursing ,Cancer ,Middle Aged ,medicine.disease ,United States ,Early Diagnosis ,General Earth and Planetary Sciences ,Early warning system ,Female ,Medical emergency ,0305 other medical science ,business - Abstract
Early warning scoring systems are tools for nurses to help monitor their patients and improve how quickly a patient experiencing a sudden decline receives clinical care. Nurse leaders and frontline staff at a major academic medical center implemented a new early warning system that gives clear guidelines to nurses, nursing assistants, and other clinicians about vital-sign parameters and changes in patients' mental status. .
- Published
- 2016
11. 2016 Updated American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards, Including Standards for Pediatric Oncology
- Author
-
Lisa Schulmeister, Kristen K. McNiff, Pamela B. Mangu, MiKaela Olsen, Kristine B. LeFebvre, Kristin M. Belderson, Tara Conti-Kalchik, Ann Von Gehr, Carolyn B. Hendricks, Amy L. Billett, Martha Polovich, Brittany E. Harvey, Terry Gilmore, and Michael N. Neuss
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Pediatric Hematology/Oncology ,MEDLINE ,Safety standards ,03 medical and health sciences ,0302 clinical medicine ,Health care ,medicine ,Pediatric oncology ,030212 general & internal medicine ,Medical prescription ,Intensive care medicine ,book ,Clinical Oncology ,Chemotherapy ,Oncology (nursing) ,business.industry ,Health Policy ,Nursing standard ,Oncology nursing ,Oncology ,030220 oncology & carcinogenesis ,Family medicine ,book.journal ,business ,Administration (government) - Abstract
Purpose To update the ASCO/Oncology Nursing Society (ONS) Chemotherapy Administration Safety Standards and to highlight standards for pediatric oncology. Methods The ASCO/ONS Chemotherapy Administration Safety Standards were first published in 2009 and updated in 2011 to include inpatient settings. A subsequent 2013 revision expanded the standards to include the safe administration and management of oral chemotherapy. A joint ASCO/ONS workshop with stakeholder participation, including that of the Association of Pediatric Hematology Oncology Nurses and American Society of Pediatric Hematology/Oncology, was held on May 12, 2015, to review the 2013 standards. An extensive literature search was subsequently conducted, and public comments on the revised draft standards were solicited. Results The updated 2016 standards presented here include clarification and expansion of existing standards to include pediatric oncology and to introduce new standards: most notably, two-person verification of chemotherapy preparation processes, administration of vinca alkaloids via minibags in facilities in which intrathecal medications are administered, and labeling of medications dispensed from the health care setting to be taken by the patient at home. The standards were reordered and renumbered to align with the sequential processes of chemotherapy prescription, preparation, and administration. Several standards were separated into their respective components for clarity and to facilitate measurement of adherence to a standard. Conclusion As oncology practice has changed, so have chemotherapy administration safety standards. Advances in technology, cancer treatment, and education and training have prompted the need for periodic review and revision of the standards. Additional information is available at http://www.asco.org/chemo-standards .
- Published
- 2017
12. National Comprehensive Cancer Network (NCCN) infusion efficiency workgroup study: Optimizing patient flow in infusion centers
- Author
-
Diana M. Cartwright, F. Marc Stewart, Connie Augustyniak, Rebecca L. Caires, Sharol K. Kidd, Daniel Mulkerin, Gina M. Szymanski, Robert W. Carlson, Marisa A. Quinn, Lisa Kimbro, Penny J. Moore, Jeanine Gordon, Rosanna Fiorarancio Fahy, MiKaela Olsen, Diedra K. Frantz, and Jessica Sugalski
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,medicine.disease ,Patient flow ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Oncology ,030220 oncology & carcinogenesis ,Emergency medicine ,Medicine ,Workgroup ,business - Abstract
e18502Background: The National Comprehensive Cancer Network (NCCN) formed an Infusion Efficiency Workgroup to determine best practices for operating efficient and effective infusion centers. Method...
- Published
- 2018
13. Hematologic Malignancies in Adults
- Author
-
MiKaela Olsen, Laura J. Zitella, MiKaela Olsen, and Laura J. Zitella
- Subjects
- Lymphoproliferative disorders, Hematopoietic system--Cancer
- Abstract
More than 180 years since Thomas Hodgkin identified the first hematologic malignancy, nurses are still learning the best ways to treat patients with these complex cancers. Hematologic Malignancies in Adults gives you comprehensive information on treatments, complications, and toxicity management for your everyday practice. The book focuses on the management of disease-related manifestations and treatment-related side effects and toxicities. You'll find details on forms of hematologic malignancies, including leukemia and lymphoma, Hodgkin lymphoma, mature T-cell and NK-cell neoplasms, and multiple myeloma. Also included is a chapter on vascular access and a listing of drugs used in the treatment of hematologic malignancies. The management of patients with myeloid and lymphoid neoplasms is unique, complex, and vital to ensuring successful outcomes and improved quality of life. This book gives you every tool you need to keep pace with the advances in medicine and science as you treat patients with hematologic malignancies.
- Published
- 2014
14. Chemotherapy and Biotherapy Guidelines and Recommendations for Practice (4th Ed.)
- Author
-
Martha Polovich, MiKaela Olsen, Kristine B. LeFebvre, Martha Polovich, MiKaela Olsen, and Kristine B. LeFebvre
- Subjects
- Antineoplastic agents, Tumors--Drug therapy
- Abstract
Order your copy of the fourth edition of this resource to keep up to date on the latest chemotherapy, biotherapy, and targeted agents. This new edition has been updated to reflect the current procedures and practices. To help readers find the content and information that they need quickly and easily, the text has been reorganized and is now divided into 11 chapters ranging from an overview of cancer and cancer treatment and principles of antineoplastic therapy to post-treatment care and competencies in chemotherapy administration. Patient education information has also been expanded to emphasize importance of education in patient care. And finally, look for new information on chemotherapy sequencing and updates on the nursing management of treatment side effects. As with previous editions, the guidelines strive to bring readers the latest details on approved drugs, standards of practice, and available evidence
- Published
- 2014
15. Current management of fatigue and anemia in patients with cancer
- Author
-
Victoria Mock and MiKaela Olsen
- Subjects
Male ,medicine.medical_specialty ,Anemia ,Nursing assessment ,Psychological intervention ,Antineoplastic Agents ,Nursing Methodology Research ,Patient Care Planning ,Quality of life ,hemic and lymphatic diseases ,Neoplasms ,Activities of Daily Living ,medicine ,Humans ,Intensive care medicine ,Erythropoietin ,Fatigue ,Nursing Assessment ,Oncology (nursing) ,business.industry ,Oncology Nursing ,Epoetin alfa ,Cancer ,medicine.disease ,Recombinant Proteins ,Epoetin Alfa ,Oncology nursing ,Hematinics ,Quality of Life ,Female ,business ,Psychosocial ,medicine.drug - Abstract
Objectives To describe the management of fatigue and anemia in patients with cancer. Data sources Published literature and clinical experience. Conclusion Anemia is a common cause of cancer-related fatigue. Epoetin alfa increases hemoglobin, decreases transfusion requirements, and improves energy and quality of life in patients with cancer-related anemia. Nonpharmacologic treatment options include exercise, nutrition optimization, and psychosocial interventions. Effective management of fatigue improves overall cancer treatment, quality of life, and functional status. Implications for nursing practice Fatigue and anemia are commonly undertreated complications of cancer and its treatment. Oncology nurses play a key role in identifying and managing these conditions.
- Published
- 2004
16. An electronic chemotherapy administration safety checklist: The safe transition from paper to computer
- Author
-
Allen R. Chen, Marie Swisher, Elizabeth Taffe, Kathy Mooney, Jackie McCready, Monica Wilt, Denise Daniel, Sharon Krumm, Melanie Cohen, Barbara Van de castle, and MiKaela Olsen
- Subjects
Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,Pharmacy ,Medication administration ,medicine.disease ,Checklist ,Surgery ,Order entry ,Oncology ,Inpatient units ,Medicine ,Medical emergency ,business ,Administration (government) - Abstract
303 Background: This abstract describes the successful implementation of an electronic chemotherapy administration safety checklist and the outcomes that led to further enhancement of safe chemotherapy administration. The purpose of this abstract is to give an overview of the processes in transitioning from a paper checklist to an electronic version. Following the implementation of a paper chemotherapy administration safety checklist in 2002, this cancer center realized a significant reduction in chemotherapy errors reaching patients. The checklist became a model for many practitioners across the U.S. Our implementation of the Sunrise computerized provider order entry (CPOE) system in oncology inpatient units in 10/2009 included support for all of the 2009 ASCO/ONS chemotherapy ordering standards, and featured a two-way interface with the pharmacy system, and an electronic medication administration record. In the 12 months following its deployment, the rate of chemotherapy errors that reached the patient fell from 2.71 per 100 chemotherapy admissions using our paper system to 1.11 per 100 chemotherapy admissions using CPOE. With the advent of electronic documentation it became apparent that the paper checklist was outdated. Methods: An electronic chemotherapy checklist was implemented, replacing a paper version that had been in use for almost a decade. The proper design and implementation of the electronic version were essential to ensure that the safety achieved with the paper checklist was not compromised. After pilot testing, the checklist was implemented. Results: The electronic chemotherapy checklist was accepted by staff and resulted in a decrease in errors reaching the patient. Conclusions: The safe administration of chemotherapy is the number one priority at our cancer center. To our surprise the electronic checklist has been a welcomed addition to our armamentarium against chemotherapy errors. The checklist has enhanced independent safety checks due to required independent sign-on of the electronic system. The checklist also heightened awareness of chemotherapy safety checks, which were unchanged, leading us to believe that the paper version had become somewhat ineffective.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.